Ultragenyx Pharmaceutical (RARE) Cost of Revenue (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Cost of Revenue data on file, last reported at $30.0 million in Q1 2026.

• Quarterly Cost of Revenue rose 3.45% year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.3 million (up 24.72% YoY) and the FY2025 annual result came in at $109.0 million, up 41.56% from the prior year.
• Cost of Revenue grew to $30.0 million in Q1 2026 per RARE's latest filing, from $29.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $30.0 million in Q1 2026 and bottomed at $5.3 million in Q4 2022.
• The 5-year median for Cost of Revenue is $17.2 million (2024), against an average of $17.0 million.
• The widest annual swing landed in 2022, when Cost of Revenue jumped 163.71%; it then rose 3.45% in 2026.
• Tracing RARE's Cost of Revenue over 5 years: stood at $5.3 million in 2022, then jumped by 122.64% to $11.8 million in 2023, then soared by 44.96% to $17.2 million in 2024, then soared by 70.95% to $29.3 million in 2025, then advanced by 2.23% to $30.0 million in 2026.
• Per Business Quant, the three latest RARE Cost of Revenue figures stand at $30.0 million (Q1 2026), $29.3 million (Q4 2025), and $28.0 million (Q3 2025).

Peer Comparison